Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Nealon who started this subject	9/21/2004 4:52:16 AM
From: nigel bates	Read Replies (1) of 123

UCB says positive results from phase 3 trial of Celltech's CDP-870 BRUSSELS (AFX) - Belgian chemicals and pharmaceutical group UCB SA (Brussels: UCBBt.BR - news) said preliminary phase 3 clinical trials of CDP-870, a molecule acquired via its takeover of Celltech (LSE: CCH.L - news - msgs) this summer, showed positive results for the treatment of rheumatoid arthritis. The phase 3 trial, the last stage before drugs are submitted for regulatory approval, tested CDP-870 as a monotherapy on patients over a six month period. Roch Doliveux, chief executive officer of UCB Pharma, commented: 'CDP-870 has now clearly demonstrated its safety and efficacy, since we obtained positive results in both monotherapy and combination therapy Phase 3 clinical trials in rheumatoid arthritis.' The drug is also in phase 3 trials as a treatment for crohn's disease, for which UCB also hopes to gain regulatory approval. CDP-870 is the most advanced molecule in the former Celltech pharmaceutical pipeline acquired by UCB this summer for 2.25 bln eur.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next